Diabetes Mellitus, Type 2 Clinical Trial
Official title:
The Effect on Metabolism, Food Intake and Preferences of a Knockout Gene Variant Involved in Carbohydrate Metabolism
NCT number | NCT05375656 |
Other study ID # | F15319-03 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 8, 2022 |
Est. completion date | May 7, 2022 |
Verified date | May 2022 |
Source | Steno Diabetes Center Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Around 10% has type 2 diabetes in Greenland, despite being a practically unknown disease only six decades ago. The drastic increase is of great concern, especially considering the transition that have occurred during the same decades going from a fisher-hunter lifestyle towards a more western lifestyle. Today, traditional marine foods are still increasingly being replaced by imported foods high in refined sugar (sucrose) and starch. Furthermore, recent studies discovered that the Greenlandic population harbors a different genetic architecture behind type 2 diabetes. Hence, obtaining more knowledge on interactions between lifestyle, genetics, and metabolism is therefore crucial in order to ameliorate the growing curve, or maybe even turn it around. Sucrose intolerance is in general rare; however, it is a common condition in Greenland and other Inuit populations. Here it is caused by a genetic variant in the sucrase-isomaltase (SI) gene, resulting in complete loss of enzyme function and hence an inability to digest sucrose and some of the glycosidic bonds in starch, both carbohydrates that are not part of the traditional Inuit diet. A recent, unpublished study found the variant to be associated with lower BMI, body fat percentage, bodyweight, and lipid levels independent of the lower intake of refined sugar. This might be explained by differences in the metabolism of carbohydrates and in the gut microbiota. The healthier phenotype was confirmed by a SI knockout mouse model, which furthermore interestingly indicated that the variant might alter food and taste preferences. It is anticipated that the drastic increase in type 2 diabetes in Greenland can be explained at least partly by the complex interaction between lifestyle and genetics. Therefore, the aim is to investigate if metabolic and microbial differences can explain the healthier phenotype of the homozygous carriers of the SI variant than wildtype individuals amd perform a 3-day cross-over dietary intervention using assigning subjects to a traditional Greenlandic diet and a Western diet. Moreover, the aim is to assess whether their food and taste preferences are different. The study will help us to understand the complex interactions between lifestyle, behavior, genetics, the microbiota and the host metabolism.
Status | Completed |
Enrollment | 38 |
Est. completion date | May 7, 2022 |
Est. primary completion date | May 7, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Homozygous carriers of the c.273_274delAG variant in the SI-gene (cases) - Homozygous non-carriers of the c.273_274delAG variant in the SI-gene (controls) Exclusion Criteria: - Diagnosis of diabetes or pharmacological treatment of diabetes. - Gastrointestinal diseases such as inflammatory bowel disease, gastrointestinal cancer, and ulcer. Persons with mild gastrointestinal problems are not excluded, e.g. persons with lactose-intolerance who normally do not have any gastrointestinal problems. - Homozygous carriers of the TBC1D4 risk variant p.Arg684Ter. - Lack of compliance with the procedures in the study protocol, judged by Investigator. - For the homozygous carriers of the c.273_274delAG variant: rise in blood glucose in an oral sucrose tolerance test. |
Country | Name | City | State |
---|---|---|---|
Greenland | Maniitsoq Healthcare Center | Maniitsoq | |
Greenland | Pikialaarfik, Greenland Institute of Natural Resources | Nuussuaq |
Lead Sponsor | Collaborator |
---|---|
Steno Diabetes Center Copenhagen | Department of Food Science, University of Copenhagen, Steno Diabetes Center Greenland, The Novo Nordisk Foundation Center for Basic Metabolic Research |
Greenland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Body weight | Weight (kg). Measured when the participant is wearing light underwear. | Baseline (participant characteristics) | |
Other | Height | Height (cm). Measured when the participant is not wearing shoes. | Baseline (participant characteristics) | |
Other | Hip circumference | Hip circumference (cm). Measured when the participant is wearing light underwear. | Baseline (participant characteristics) | |
Other | Waist circumference | Waist circumference (cm). Measured when the participant is wearing light underwear. | Baseline (participant characteristics) | |
Other | Body composition | Body fat percentage measured using a Tanita body composition analyser. | Baseline (participant characteristics) | |
Other | Plasma lipodomics. | For future analyses | The day before and the day after each dietary intervention period. | |
Other | Plasma metabolomics. | For future analyses | The day before and the day after each dietary intervention period. | |
Other | Plasma proteomics. | For future analyses | The day before and the day after each dietary intervention period. | |
Other | Fecal lipodomics | For future analyses | The day before and the day after each dietary intervention period. | |
Other | Fecal metabolomics. | For future analyses | The day before and the day after each dietary intervention period. | |
Other | Fecal proteomics. | For future analyses | The day before and the day after each dietary intervention period. | |
Primary | Glycemic variability during Western diet | Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) during the whole study period, i.e. during both Western and Inuit diet and the wash-out period in between. | During the 3 days of intervention with Western diet. | |
Primary | Glycemic variability during Inuit diet | Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) during the whole study period, i.e. during both Western and Inuit diet and the wash-out period in between. | During the 3 days of intervention with Inuit diet. | |
Secondary | Sweet Bias Score | As a food reward measure, explicit liking for foods with sweet relative to savory taste will be assessed using the Leeds Food Preference Questionnaire. A sweet bias score will be estimated, where a positive score indicates higher preference for sweet relative to savoury foods and a negative score indicates higher preference for savoury foods. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Fat Bias Score | As a food reward measure, explicit liking for foods with high-fat relative to low-fat content will be assessed using the Leeds Food Preference Questionnaire. A fat bias score will be estimated, where a positive score indicates higher preference for high-fat relative to low-fat foods and a negative score indicates higher preference for low-fat foods. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | High-fat savory preference | As a food reward measure, explicit liking for high-fat savory foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Low-fat savory preference | As a food reward measure, explicit liking for low-fat savory foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | High-fat sweet preference | As a food reward measure, explicit liking for high-fat sweet foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Low-fat sweet preference | As a food reward measure, explicit liking for low-fat sweet foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Implicit wanting score: High-fat savory foods | As a food reward measure, implicit wanting for high-fat savory foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Implicit wanting score: Low-fat savory foods | As a food reward measure, implicit wanting for low-fat savory foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Implicit wanting score: High-fat sweet foods | As a food reward measure, implicit wanting for high-fat sweet foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Implicit wanting score: Low-fat sweet foods | As a food reward measure, implicit wanting for low-fat sweet foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Habitual diet | Habitual dietary intake will be assessed using a food frequency questionnaire. Macronutrient composition and content of sugar will be assessed as well as characterization of differences in food choice with respect to sweet foods and foods rich in starch. Intake will be expressed in g/day as well as E%. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Intake in a snacking test meal | Using an ad libitum snacking test meal, preferences will be assessed for sweet-taste and content of sucrose and fat as well as other sweeteners than sucrose, e.g. honey. | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Sucrose sweetness sensitivity | Ability to taste a difference between iso-intense solutions of sucrose and fructose+glucose using a 2-alternative forced choice test | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Sweet liking | Hedonic rating of liking of iso-intense solutions of sucrose, fructose, glucose and fructose+glucose using a visual analogue scale (0-100 mm) | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Perceived intensity of sugars | Hedonic rating of perceived intensity of iso-intense solutions of sucrose, fructose, glucose and fructose+glucos using a visual analogue scale (0-100 mm) | Baseline (to assess differences between genotypes, independent of the intervention) | |
Secondary | Plasma lipids | Changes in fasting plasma measures of VLDL-cholesterol, LDL-cholesterol, HDL-cholesterol, total cholesterol, remnant cholesterol, and triglycerides | The day before and the day after each dietary intervention period. | |
Secondary | Serum insulin | Changes in serum insulin. Fasting sample. | The day before and the day after each dietary intervention period. | |
Secondary | Plasma CRP | Changes in plasma CRP. Fasting sample. | The day before and the day after each dietary intervention period. | |
Secondary | Plasma acetate | Changes in plasma acetate. Fasting sample. | The day before and the day after each dietary intervention period. | |
Secondary | Plasma propionate | Changes in plasma propionate. Fasting sample. | The day before and the day after each dietary intervention period. | |
Secondary | Plasma butyrate | Changes in plasma butyrate. Fasting sample. | The day before and the day after each dietary intervention period. | |
Secondary | HbA1c | Fasting glycated hemoglobin | Baseline | |
Secondary | Fecal acetate | Changes in fecal acetate. | Before and on the last day or on the day after each dietary intervention period. | |
Secondary | Fecal propionate | Changes in fecal propionate. | Before and on the last day or on the day after each dietary intervention period. | |
Secondary | Fecal butyrate | Changes in fecal butyrate. | Before and on the last day or on the day after each dietary intervention period. | |
Secondary | Fecal pH | pH of fecal samples. | Before and on the last day or on the day after each dietary intervention period. | |
Secondary | Changes in gut microbiota composition | Changes in gut microbiota composition between baseline and end of each dietary intervention period. Microbiota composition is measured by genome sequencing fecal samples. | Before and on the last day or on the day after each dietary intervention period. | |
Secondary | Baseline gut microbiota composition | Characterization of the gut microbiota composition. Microbiota composition is measured by genome sequencing fecal samples. | Before intervention (baseline). | |
Secondary | Fecal carbohydrates | Content of carbohydrates in fecal samples and changes in this during the intervention periods. | Before and on the last day or on the day after each dietary intervention period. | |
Secondary | Glycemic variability during habitual diet | Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) | Measured during 7 days of wash-out |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |